Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.

Boostrom SY, Nagorney DM, Donohue JH, Harmsen S, Thomsen K, Que F, Kendrick M, Reid-Lombardo KM.

J Gastrointest Surg. 2009 Nov;13(11):2003-9; discussion 2009-10. doi: 10.1007/s11605-009-1007-3. Epub 2009 Sep 16.

2.

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK.

Int J Colorectal Dis. 2010 Oct;25(10):1243-9. doi: 10.1007/s00384-010-0996-4. Epub 2010 Jun 24.

3.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

4.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.

Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.

PMID:
24585720
5.

Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.

Faron M, Chirica M, Tranchard H, Balladur P, de Gramont A, Afchain P, Andre T, Paye F.

J Gastrointest Cancer. 2014 Sep;45(3):298-306. doi: 10.1007/s12029-014-9594-y.

PMID:
24610400
6.

[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].

Amano R, Yamada N, Noda E, Kubo N, Tanaka H, Muguruma K, Inoue T, Yashiro M, Maeda K, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K.

Gan To Kagaku Ryoho. 2009 Nov;36(12):2003-5. Japanese.

PMID:
20037305
7.

Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?

Kataoka K, Kanazawa A, Iwamoto S, Kato T, Nakajima A, Arimoto A.

World J Surg. 2014 Apr;38(4):936-46. doi: 10.1007/s00268-013-2305-1.

PMID:
24166026
8.

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H.

Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4.

9.

Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.

Hsu HC, Chou WC, Shen WC, Wu CE, Chen JS, Liau CT, Lin YC, Yang TS.

Anticancer Res. 2013 Aug;33(8):3317-25.

PMID:
23898098
10.

Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.

Popov IP, Milicevic M, Kecmanovic D, Tomasevic Z, Radosevic-Jelic Lj, Borojevic N, Micev MT, Kezic I.

J Exp Clin Cancer Res. 2006 Sep;25(3):313-9.

PMID:
17167970
11.

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S.

BMC Cancer. 2009 May 20;9:156. doi: 10.1186/1471-2407-9-156.

12.

Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Lubezky N, Geva R, Shmueli E, Nakache R, Klausner JM, Figer A, Ben-Haim M.

World J Surg. 2009 May;33(5):1028-34. doi: 10.1007/s00268-009-9945-1.

PMID:
19234865
13.

The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.

Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, Lobo DN.

Virchows Arch. 2007 Nov;451(5):943-8. Epub 2007 Sep 6.

PMID:
17805566
14.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
15.

Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.

Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB.

Oncology. 2013;85(5):283-9. doi: 10.1159/000355475. Epub 2013 Nov 6.

PMID:
24217184
16.

[Neoadjuvant therapy concepts for liver metastases].

Folprecht G, Bechstein WO.

Chirurg. 2011 Nov;82(11):989-94. doi: 10.1007/s00104-011-2131-7. Review. German.

PMID:
22033894
17.

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.

Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M.

BMC Cancer. 2014 Mar 11;14:174. doi: 10.1186/1471-2407-14-174.

18.

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, Geboes K, Peeters M.

Br J Cancer. 2012 Jun 5;106(12):1926-33. doi: 10.1038/bjc.2012.184. Epub 2012 May 17.

19.

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.

Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5. Epub 2010 Oct 24.

PMID:
20972872
20.

Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.

Umehara M, Umehara Y, Takahashi K, Murata A, Nishikawa S, Tokura T, Matsuzaka M, Tanaka R, Morita T.

Anticancer Res. 2016 Apr;36(4):1949-54.

PMID:
27069185

Supplemental Content

Support Center